5 result(s) displayed (1 - 5 of 5):

'Tis the season for divestitures (from Corporate Dealmaker)

Economic slowdowns usually give rise to corporate sell-offs. But doesn't it seem that there are an unusual number of high-profile divestitures in the news right now? Consider:Dr Pepper Snapple Group Inc. is now officially independent from Cadbury plc, having begun trading Wednesday on the NYSE.  Auto parts maker ArvinMeritor Inc. said Tuesday...

Posted on May 7, 2008 1:55 PM

IPO plans for Mead Johnson, but Bristol's options are open (from Corporate Dealmaker)

Since Bristol-Myers Squibb Co. announced a strategic review for its Mead Johnson division, maker of infant formula Enfamil and other products, there's been speculation -- some of it here -- about who might buy the unit. Thursday, along with its quarterly results, the restructuring company announced the following:Bristol-Myers Squibb currently...

Posted on April 24, 2008 11:10 AM

Pharma strategists discovered by WSJ (from Corporate Dealmaker)

An article in Monday morning's Wall Street Journal notes: "As the drug industry wrestles with major challenges, some top companies are turning to a new kind of executive for help: strategy master." Well, sort of. It's true that Big Pharma's well publicized troubles have resulted in some high-profile hires at...

Posted on April 14, 2008 3:56 PM

After Alcon deal, Nestle well positioned to bid for Mead Johnson (from Corporate Dealmaker)

News of Novartis AG buying Alcon Inc. from Nestle SA brings several thoughts to mind. The first, noted in Andrew Bulkeley's article in The Deal, is that the $11 billion in cash Nestle will reap in the first step of the deal is more than enough to pay for the...

Posted on April 7, 2008 1:42 PM

Healthcare symposium insights: Dance of the pharma-biotech dealmakers (from Corporate Dealmaker)

The creative use of bio-bucks, trends in due diligence and the latest on the balance of power in the industry were the key takeaways Wednesday when dealmakers from four prominent companies shared their thoughts in a couple of sessions at The Deal's Healthcare Dealmaking Symposium in New York.It's no secret...

Posted on March 20, 2008 3:23 PM